Aprea Therapeutics

Halda Therapeutics Appoints Dr. Eyal Attar as Chief Medical Officer to Advance Novel RIPTAC Cancer Platform

a month ago

• Dr. Eyal Attar joins Halda Therapeutics as Chief Medical Officer, bringing over 25 years of biotechnology R&D and clinical trial experience to advance the company's novel RIPTAC cancer therapy platform. • Halda is currently conducting a Phase 1/2 clinical trial of HLD-0915, their lead candidate targeting metastatic castration-resistant prostate cancer (mCRPC) through a unique "hold and kill" mechanism designed to overcome resistance. • The RIPTAC platform represents a new therapeutic modality that creates neomorphic protein-protein interactions to selectively target cancer cells, with programs in development for prostate cancer, breast cancer, and other serious diseases.

Aprea Therapeutics Advances APR-1051 Clinical Trial with First HPV+ Head and Neck Cancer Patient Dosed

2 months ago

• Aprea Therapeutics has dosed the first HPV+ head and neck squamous cell carcinoma (HNSCC) patient in Cohort 5 of the ACESOT-1051 trial, evaluating their WEE1 kinase inhibitor APR-1051. • The company recently established a Material Transfer Agreement with MD Anderson Cancer Center to explore APR-1051's potential in treating HPV+ and HPV- HNSCC with genomic markers of replication stress. • Open label data from the ACESOT-1051 clinical trial is expected in the second half of 2025, with researchers noting encouraging safety profiles to date.

Aprea Therapeutics Optimizes ATRN-119 Dosing in Phase 1/2a Trial for Advanced Solid Tumors

5 months ago

• Aprea Therapeutics initiates twice-daily dosing of ATRN-119 at 550mg in the ABOYA-119 Phase 1/2a trial to maintain optimal therapeutic levels. • The trial evaluates ATRN-119 as a monotherapy for advanced solid tumors with DNA damage response gene mutations, potentially enhancing efficacy. • Phase 1 readout is anticipated in the second half of 2025, with dose escalation continuing independently for both once-daily and twice-daily schedules. • ATRN-119 is the first macrocyclic ATR inhibitor in clinical trials and the only one tested as a monotherapy on a continuous twice-daily schedule.

Adicet Bio's ADI-001 Receives FDA Fast Track for Refractory SLE, Expands Autoimmune Pipeline

6 months ago

• Adicet Bio's ADI-001 receives FDA Fast Track designation for refractory systemic lupus erythematosus (SLE) with extrarenal involvement, expediting its development. • A Phase 1 trial is underway, evaluating ADI-001 across six autoimmune indications, including lupus nephritis (LN), SLE, systemic sclerosis (SSc), and others, with preliminary data expected in 2025. • ADI-001, an allogeneic gamma delta CAR T-cell therapy targeting CD20, has shown promising B-cell depletion in preclinical studies, suggesting potential as an off-the-shelf treatment. • Adicet Bio is also advancing ADI-270, a CAR T-cell therapy for metastatic clear cell renal cell carcinoma (ccRCC), with Phase 1 data anticipated in the first half of 2025.

Aprea Therapeutics Advances WEE1 and ATR Inhibitors in Clinical Trials

6 months ago

• Aprea Therapeutics is progressing its Phase 1 ACESOT-1051 trial of APR-1051, a WEE1 inhibitor, showing promising tolerability in treating cancers with Cyclin E over-expression. • The company's Phase 1/2a ABOYA-119 study is evaluating ATRN-119, an ATR inhibitor, for patients with DDR-related gene mutations, addressing a significant unmet medical need. • Aprea Therapeutics reported $26.2 million in cash reserves, ensuring funding for at least the next twelve months, and appointed Dr. Philippe Pultar as a senior medical advisor.